Skip to main content
HEMOGENYX PHARMACEUTICALS PLC logo

HEMOGENYX PHARMACEUTICALS PLC — Investor Relations & Filings

Ticker · HEMO ISIN · GB00BYX3WZ24 LEI · 2138008L93GYU5GN6179 IL Manufacturing
Open in API
Filings indexed 473 across all filing types
Latest filing 2025-09-01 Capital/Financing Update
Country GB United Kingdom
Listing IL HEMO

About HEMOGENYX PHARMACEUTICALS PLC

https://hemogenyx.com/

Hemogenyx Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for life-threatening diseases. The company develops treatments for blood and autoimmune diseases, as well as viral infections. Its core technology includes advanced cell-based therapies, such as its proprietary Chimeric Antigen Receptor (CAR) T-cell platform, HEMO-CAR-T, which is being developed for the potential treatment of Acute Myeloid Leukemia (AML).

Recent filings

Filing Released Lang Actions
Issue of convertible loan notes
Capital/Financing Update Classification · 100% confidence The document is an announcement from Hemogenyx Pharmaceuticals regarding the issuance of convertible loan notes to raise £620,000. This falls under the category of company fundraising and financing activities. According to the provided definitions, 'Capital/Financing Update' (CAP) is the correct classification for updates on company fundraising and financing activities.
2025-09-01 English
Result of Audit Tender
Audit Report / Information Classification · 95% confidence The document is a short announcement (under 5,000 characters) issued via the London Stock Exchange's RNS service. It details the outcome of an audit tender process, specifically the intention to re-appoint an auditor. Since it is a regulatory announcement regarding corporate governance/administrative updates and does not fit into more specific categories like 'Audit Report' (which would be the actual audit document) or 'Board/Management Information' (which focuses on personnel changes), it is best classified as a general Regulatory Filing (RNS). FY 2025
2025-08-29 English
Hemogenyx raises £570,000 and Director's Dealing
Regulatory Filings Classification · 98% confidence The document is a regulatory announcement from Hemogenyx Pharmaceuticals regarding a capital raise (allotment of new shares) and includes a mandatory Director's Dealing notification (PDMR transaction). While it contains elements of both 'Capital/Financing Update' (CAP) and 'Director's Dealing' (DIRS), the primary purpose of the RNS filing is to announce the capital raise and the issuance of new shares to fund clinical trials. Given the dual nature, 'CAP' is the most appropriate classification for the primary corporate action described.
2025-08-26 English
Third Patient Treated with HG-CT-1 CAR-T Therapy
Regulatory Filings Classification · 100% confidence The document is a press release distributed via the Regulatory News Service (RNS) regarding a clinical trial milestone for Hemogenyx Pharmaceuticals. It details the treatment of a third patient and the completion of a dose cohort. Since it is a general corporate announcement regarding operational progress that does not fit into specific categories like financial reports, dividends, or board changes, it falls under the RNS (Regulatory Filings) category.
2025-08-15 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a regulatory announcement from Hemogenyx Pharmaceuticals plc regarding 'Total Voting Rights'. It provides the total number of issued shares and voting rights to assist shareholders in complying with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules. This type of disclosure is a standard regulatory requirement for listed companies and does not fit into specific categories like M&A, dividends, or financial reports. Therefore, it is classified as a general regulatory filing (RNS).
2025-07-31 English
Placing to Raise £250,000 and Director’s Dealing
Director's Dealing Classification · 98% confidence The document is a regulatory announcement from Hemogenyx Pharmaceuticals regarding a capital raise (allotment of new shares) and a director's dealing notification. While it contains information about a director's transaction, the primary purpose of the filing is to announce a capital raise and share issuance. According to the provided definitions, 'Share Issue/Capital Change' (SHA) is the most accurate classification for announcements regarding new share issues and capital changes, even when accompanied by director dealing disclosures.
2025-07-29 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.